- Home
- App Analytics
- respiri™ US
- respiri™ US Vs. MetaNose
respiri™ US vs MetaNose Usage & Stats
wheezo® WheezeRate detector is a smartphone-based system consisting of a wheezo® breath sensor^, (device) and the respiriTM app. The device^ works with the respiriTM mobile app to record and track wheeze and returns a wheeze rate for each breath recording. You can build a personal profile to share a WheezeRate history, breath sound recordings and self-reported data with your physicians. Wheeze recordings are available for your physician’s immediate review and playback.
wheezo® is for adults and children from 2 years. It is not for diagnostic use. Your healthcare professional’s advice is required to understand wheezo® readings.
It’s an easy way to keep track of wheeze every day and store a record of wheeze rates. Recordings also contain environmental information; weather, pollen counts & air irritant information present at the time of recordings. In addition, the respiriTM app supports you to log and track self-reported symptoms, triggers and medication usage.
--------------------------------------------------------------------------------------------------------------------------
Key features:
Detects wheeze with the wheezo® breath sensor^
Wheeze recordings are available for your physician’s immediate review and playback.
Supports easy logging of symptoms, triggers & medication usage
Input your self-reported symptoms, triggers and medication use over time.
Set medication reminders.
Air irritants & pollen counts
- Check live air quality; air irritants and pollen counts down to the zip code you are in, anywhere in the US in real time. You can also view forecasts.
Healthcare provider sharing
- Share a detailed history with your healthcare provider(s)
- Keep a record of and review your wheeze rates, wheeze recordings and history including self-reported symptoms, triggers, medication usage and environmental information.
- Wheeze recordings are stored with the environmental and weather data, like pollen counts and air irritants which were present at the time of recording.
Over time, by working with your healthcare providers and increasing your shared awareness with more data, your healthcare providers can work with you to gain a better understanding of your wheeze.
--------------------------------------------------------------------------------------------------------------------------
^wheezo® breath sensor provided separately
Limitations of Use and Contraindications
wheezo® is not intended for diagnostic use. wheezo® is intended to detect and record abnormal breath sounds (continuous adventitious breath sounds or CABS) at the windpipe (trachea), reported as WheezeRate in adults and children (2 years and older).
A licensed health care professional’s advice is required to understand the meaning and importance of the wheezo® readings.
Warnings
If the user is feeling breathless, or experiencing other symptoms, it is important to prioritise treatment over taking a wheeze rate. Do not delay treatment.
Regardless of the wheeze rate, if the user has signs and symptoms such as chest tightness, shortness of breath, coughing or wheezing, they should always follow their healthcare professional’s advice.
This information is intended for the use of patients and providers in the United States.
Terms of Use: respiri.co/us/website-terms-of-use
Privacy policy: respiri.co/us/privacy-policy
App terms and conditions: respiri.co/us/app-terms-and-conditions
- Apple App Store
- Free
- Health & Fitness
Store Rank
- -
MetaNose APP is a mobile APP for connecting to the MetaNose breath sensor to provide better user experience. It also allows the users to check historical measurements.
- Apple App Store
- Free
- Health & Fitness
Store Rank
- -
respiri™ US vs. MetaNose ranking comparison
Compare respiri™ US ranking trend in the past 28 days vs. MetaNose
Rank
No Data Available
respiri™ US vs. MetaNose ranking by country comparison
Compare respiri™ US ranking trend in the past 28 days vs. MetaNose
No Data to Display
Compare to any site with our free trial
respiri™ US VS.
MetaNose
December 15, 2024